georgeclerk
Guggenheim downgraded Alumis (ALMS) to Neutral from Buy after the company reported a mid-stage trial setback for its lead asset, envudeucitinib, in systemic lupus erythematosus, an autoimmune condition affecting multiple organs.
Noting that its Phase 2b LUMUS study failed in